Cited 36 times in
Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2023-08-09T02:43:18Z | - |
dc.date.available | 2023-08-09T02:43:18Z | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 0022-1899 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195777 | - |
dc.description.abstract | Background: Antiviral treatment for hepatitis B virus (HBV) e antigen (HBeAg)-positive chronic HBV infection is still controversial. We assessed whether antiviral treatment reduces the risk of liver disease progression in these patients. Methods: This study included consecutive patients in 8 large-volume hospitals in Korea who tested positive for HBeAg and had an HBV DNA level of >20000 IU/mL, an alanine aminotransferase (ALT) level of <40 IU/L, and no evidence of cirrhosis. The primary end point was the development of hepatocellular carcinoma (HCC), and the secondary end point was the development of cirrhosis. Results: A total of 484 patients were included: 87 were in the antiviral treatment group, and 397 were in the control group. Baseline liver function was significantly more favorable for the control group. After matching for propensity score to overcome those differences, the antiviral treatment group had a significantly reduced risk for HCC (hazard ratio [HR], 0.234; log-rank P = .046) and cirrhosis (HR, 0.235; log-rank P = .015), compared with the control group. After balancing the baseline characteristics by using inverse probability weighting, antiviral therapy significantly decreased the risk of HCC (HR, 0.189; log-rank P = .004) and cirrhosis (HR, 0.347; log-rank P = .036). Conclusion: Antiviral therapy for patients with HBeAg-positive chronic HBV infection and have a high HBV load reduces the risk of HCC, even if the ALT level is below the upper limit of normal. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | JOURNAL OF INFECTIOUS DISEASES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Alanine Transaminase / blood | - |
dc.subject.MESH | Antiviral Agents / therapeutic use* | - |
dc.subject.MESH | Carcinoma, Hepatocellular / virology | - |
dc.subject.MESH | DNA, Viral / blood | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Hepatitis B e Antigens / blood | - |
dc.subject.MESH | Hepatitis B e Antigens / immunology* | - |
dc.subject.MESH | Hepatitis B virus / drug effects* | - |
dc.subject.MESH | Hepatitis B virus / pathogenicity* | - |
dc.subject.MESH | Hepatitis B, Chronic / drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Cirrhosis / virology | - |
dc.subject.MESH | Liver Neoplasms / virology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Nucleosides / therapeutic use* | - |
dc.subject.MESH | Nucleotides / therapeutic use* | - |
dc.subject.MESH | Pharmacogenomic Testing | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Young Chang | - |
dc.contributor.googleauthor | Won Hyeok Choe | - |
dc.contributor.googleauthor | Dong Hyun Sinn | - |
dc.contributor.googleauthor | Jeong-Hoon Lee | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Hyewon Lee | - |
dc.contributor.googleauthor | Jae-Jun Shim | - |
dc.contributor.googleauthor | Dae Won Jun | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.contributor.googleauthor | Joon Yeul Nam | - |
dc.contributor.googleauthor | Eun Ju Cho | - |
dc.contributor.googleauthor | Su Jong Yu | - |
dc.contributor.googleauthor | Dong Ho Lee | - |
dc.contributor.googleauthor | Jeong Min Lee | - |
dc.contributor.googleauthor | Yoon Jun Kim | - |
dc.contributor.googleauthor | So Young Kwon | - |
dc.contributor.googleauthor | Seung Woon Paik | - |
dc.contributor.googleauthor | Jung-Hwan Yoon | - |
dc.identifier.doi | 10.1093/infdis/jix506 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J01454 | - |
dc.identifier.eissn | 1537-6613 | - |
dc.identifier.pmid | 29029102 | - |
dc.identifier.url | https://academic.oup.com/jid/article/216/11/1407/4210686 | - |
dc.subject.keyword | Immune-tolerant phase | - |
dc.subject.keyword | antiviral treatment | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | liver cirrhosis | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 216 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1407 | - |
dc.citation.endPage | 1414 | - |
dc.identifier.bibliographicCitation | JOURNAL OF INFECTIOUS DISEASES, Vol.216(11) : 1407-1414, 2017-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.